{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Schworer EK"],"funding":["National Center for Advancing Translational Sciences","NICHD NIH HHS","NCATS NIH HHS","NIA NIH HHS","National Institute of Child Health and Human Development","National Institute on Aging"],"pagination":["1214-1224"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12207984"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["23(12)"],"pubmed_abstract":["<h4>Background</h4>Adults with Down syndrome are at risk for Alzheimer's disease. Natural history cohort studies have characterised the progression of Alzheimer's disease biomarkers in people with Down syndrome, with a focus on amyloid β-PET and tau-PET. In this study, we aimed to leverage these well characterised imaging biomarkers in a large cohort of individuals with Down syndrome, to examine the timeline to symptomatic Alzheimer's disease based on estimated years since the detection on PET of amyloid β-positivity, referred to here as amyloid age, and in relation to tau burden as assessed by PET.<h4>Methods</h4>In this prospective, longitudinal, observational cohort study, data were collected at four university research sites in the UK and USA as part of the Alzheimer's Biomarker Consor"],"journal":["The Lancet. Neurology"],"pubmed_title":["Timeline to symptomatic Alzheimer's disease in people with Down syndrome as assessed by amyloid-PET and tau-PET: a longitudinal cohort study."],"pmcid":["PMC12207984"],"funding_grant_id":["P50 AG008702","R01 AG080766","UL1 TR002373","T32 HD007489","UL1 TR001873","UL1 TR002345","P30 AG062421","U54 HD087011","P50 AG005681","UL1 TR001414","U19 AG068054","P50 HD105353","P50 AG005133","UL1 TR001857","P30 AG062715","P30 AG066519","U24 AG021886","P30 AG066462","R01 AG070028","U01 AG051412","U01 AG051406","K99 AG084738","U54 HD090256","P50 AG016570"],"pubmed_authors":["Zammit MD","Zhang F","Zaman S","Clark L","O'Bryant S","Schupf N","Cheema A","Minhas D","Nadkarni N","Wang J","Zaman SH","Clare I","Varadarajan B","Constantino J","Henson R","Handen BL","Honig L","Reiman E","Kofler J","Alzheimer's Biomarker Consortium–Down Syndrome (ABC–DS)","Keator D","Pang D","Mapstone M","Mathis C","Christian BT","Chen K","Feingold E","Rosas D","Foroud T","Betthauser T","Fagan A","Tudorascu DL","Klunk W","Parisi M","Schworer EK","Hartley S","Bulova P","Head E","Doran E","Pulsifer M","Aizenstein H","Petersen M","Laymon CM","Rizvi B","Ryan L","Jordan C","Lai F","Tudorascu D","Lee J","Birn R","Ances BM","Ances B","Johnson S","Andrews H","Lott I","Tycko B","Krinsky-McHale S","Rafii M","White D","Yassa M","Cohen AD","Christian B","Price J","Hom C","Harp J","Brickman A","Handen B","Tumuluru R","Kreisl W","Bell K","Ikonomovic M","Laymon C","Schmitt F","Cohen A","Hartley SL","Kamboh MI","Lao P","Lupson V","Silverman W"],"additional_accession":[]},"is_claimable":false,"name":"Timeline to symptomatic Alzheimer's disease in people with Down syndrome as assessed by amyloid-PET and tau-PET: a longitudinal cohort study.","description":"<h4>Background</h4>Adults with Down syndrome are at risk for Alzheimer's disease. Natural history cohort studies have characterised the progression of Alzheimer's disease biomarkers in people with Down syndrome, with a focus on amyloid β-PET and tau-PET. In this study, we aimed to leverage these well characterised imaging biomarkers in a large cohort of individuals with Down syndrome, to examine the timeline to symptomatic Alzheimer's disease based on estimated years since the detection on PET of amyloid β-positivity, referred to here as amyloid age, and in relation to tau burden as assessed by PET.<h4>Methods</h4>In this prospective, longitudinal, observational cohort study, data were collected at four university research sites in the UK and USA as part of the Alzheimer's Biomarker Consor","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Dec","modification":"2026-06-09T05:40:10.783Z","creation":"2026-06-09T03:08:01.91Z"},"accession":"S-EPMC12207984","cross_references":{"pubmed":["39577922"],"doi":["10.1016/S1474-4422(24)00426-5","10.1016/s1474-4422(24)00426-5"]}}